

# LÃ©onor Benhaim

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9071408/publications.pdf>

Version: 2024-02-01

28  
papers

1,151  
citations

516710  
16  
h-index

610901  
24  
g-index

29  
all docs

29  
docs citations

29  
times ranked

2348  
citing authors

#	ARTICLE	IF	CITATIONS
1	Multiplex Picodroplet Digital PCR to Detect KRAS Mutations in Circulating DNA from the Plasma of Colorectal Cancer Patients. <i>Clinical Chemistry</i> , 2013, 59, 1722-1731.	3.2	429
2	Linear Relationship of Peritoneal Cancer Index and Survival in Patients with Peritoneal Metastases from Colorectal Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 114-119.	1.5	118
3	Metastatic colorectal cancer (mCRC): French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). <i>Digestive and Liver Disease</i> , 2019, 51, 1357-1363.	0.9	80
4	ERBB2 gene as a potential therapeutic target in small bowel adenocarcinoma. <i>European Journal of Cancer</i> , 2014, 50, 1740-1746.	2.8	79
5	Adjuvant Chemotherapy After Resection of Colorectal Liver Metastases in Patients at High Risk of Hepatic Recurrence. <i>Annals of Surgery</i> , 2013, 257, 114-120.	4.2	76
6	Prospective Validation of Candidate SNPs of VEGF/VEGFR Pathway in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Plus Bevacizumab. <i>PLoS ONE</i> , 2013, 8, e66774.	2.5	64
7	Laparoscopic Versus Open Surgery for Gastric Gastrointestinal Stromal Tumors. <i>Annals of Surgery</i> , 2015, 262, 831-840.	4.2	49
8	Survival after complete cytoreductive surgery and HIPEC for extensive pseudomyxoma peritonei. <i>Surgical Oncology</i> , 2019, 29, 78-83.	1.6	38
9	Conversion to Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma After Bidirectional Chemotherapy. <i>Annals of Surgical Oncology</i> , 2017, 24, 3640-3646.	1.5	25
10	Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS). <i>European Journal of Cancer</i> , 2021, 159, 24-33.	2.8	24
11	Ninety percent of the adverse outcomes occur in 10% of patients: can we identify the populations at high risk of developing peritoneal metastases after curative surgery for colorectal cancer?. <i>International Journal of Hyperthermia</i> , 2017, 33, 505-510.	2.5	22
12	Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial "PACHA-01 (NCT02494973). <i>BMC Cancer</i> , 2018, 18, 787.	2.6	22
13	Peritoneal and extraperitoneal relapse after previous curative treatment of peritoneal metastases from colorectal cancer: What survival can we expect?. <i>European Journal of Cancer</i> , 2018, 100, 94-103.	2.8	20
14	Can a Benefit be Expected from Surgical Debulking of Unresectable Pseudomyxoma Peritonei?. <i>Annals of Surgical Oncology</i> , 2016, 23, 1618-1624.	1.5	19
15	"Decision for adjuvant treatment in stage II colon cancer based on circulating tumor DNA:The CIRCULATE-PRODIGE 70 trial". <i>Digestive and Liver Disease</i> , 2020, 52, 730-733.	0.9	18
16	Peritoneal Metastases from Colorectal Cancer. <i>Surgical Oncology Clinics of North America</i> , 2018, 27, 563-583.	1.5	17
17	Ovarian Metastasis Is Associated with Retroperitoneal Lymph Node Relapses in Women Treated for Colorectal Peritoneal Carcinomatosis. <i>Annals of Surgical Oncology</i> , 2013, 20, 491-496.	1.5	14
18	Strategies to prevent peritoneal carcinomatosis arising from colorectal cancer. <i>Future Oncology</i> , 2017, 13, 907-918.	2.4	12

#	ARTICLE	IF	CITATIONS
19	Radiofrequency ablation for colorectal cancer liver metastases initially greater than 25Âmm but downsized by neo-adjuvant chemotherapy is associated with increased rate of local tumor progression. Hpb, 2018, 20, 76-82.	0.3	11
20	Strategies for Managing Intraoperative Discovery of Limited Colorectal Peritoneal Metastases. Annals of Surgical Oncology, 2019, 26, 1437-1444.	1.5	6
21	Long-Term Results after Surgical Resection of Peritoneal Metastasis from Neuroendocrine Tumors. Neuroendocrinology, 2021, 111, 599-608.	2.5	3
22	Abstract 5235: Circulating tumor DNA as a prognostic marker in colorectal cancer: Preliminary results of a prospective trial. Cancer Research, 2015, 75, 5235-5235.	0.9	3
23	Cetuximabâ€”an option for unresectable CRC liver metastases. Nature Reviews Clinical Oncology, 2013, 10, 374-375.	27.6	1
24	Gender specific profiling in SCN1A polymorphisms and time to recurrence in patients with stage II/III colorectal cancer.. Journal of Clinical Oncology, 2013, 31, 393-393.	1.6	1
25	Hepatic Resection for Extrahepatic Metastatic Disease: When Is It Reasonable?. Current Colorectal Cancer Reports, 2015, 11, 78-83.	0.5	0
26	ERBB2 gene as a potential therapeutic target in small bowel adenocarcinoma.. Journal of Clinical Oncology, 2014, 32, 205-205.	1.6	0
27	Can we use radiofrequency ablation for liver metastases from colorectal cancer over 25 mm initially but downsized by systemic chemotherapy?. Journal of Clinical Oncology, 2015, 33, 3528-3528.	1.6	0
28	Genetic variants of kinases suppressors of Ras (KSR) to predict tumor response to first-line cetuximab in patients with mCRC: Prospective analysis in the FIRE 3 trial.. Journal of Clinical Oncology, 2015, 33, 3613-3613.	1.6	0